Cadence Partners with Antiviral Discovery Consortium to Spearhead Rapid Development of Treatments for Viral Pandemics

Rhea-AI Summary

Cadence Molecular Sciences (OpenEye), a business unit of Cadence Design Systems (Nasdaq: CDNS), is providing molecular design software to power the open-science AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium. The $68 million NIH grant will support the development of antivirals to prevent future pandemics. The ASAP Consortium aims to deliver multiple drug candidates ready for evaluation in humans in the event of an ongoing or emerging pandemic threat. OpenEye's software will aid in advancing therapeutics for under-researched diseases and preparing for pandemics.

Antiviral Discovery Effort Funded by $68M NIH Grant

SANTA FE, N.M.--(BUSINESS WIRE)-- Cadence Molecular Sciences (OpenEye)—a business unit of Cadence Design Systems (Nasdaq: CDNS)—will provide OpenEye’s molecular design software to power the open-science AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium in support of an innovative effort to rapidly develop antivirals to prevent future pandemics.

John D. Chodera, PhD, a lab head at the Memorial Sloan Kettering Cancer Center (MSKCC), directs the researchers and software scientists building the computational chemistry infrastructure to support ASAP.

“Dr. Chodera and the ASAP scientists working with him will have access to OpenEye tools to help support the ASAP Discovery Consortium and antiviral drug research,” said Anthony Nicholls, PhD, corporate vice president, OpenEye, Cadence Molecular Sciences. “OpenEye’s software will aid in advancing therapeutics for under-researched diseases and to prepare for pandemics.”

OpenEye’s Applications, Toolkits and Orion® platform—which include ROCS®, FastROCS™, BROOD, OMEGA, OEChemTK, Grapheme™, Nonequilibrium Switching (NES) Free Energy Calculations and other tools—enable computational chemists working with the ASAP Discovery Consortium to build a robust antiviral drug discovery pipeline using technology, structural biology, artificial intelligence (AI), machine learning and computational chemistry.

“Open-science drug discovery against future pandemics is an essential public service,” said Chodera. “We are thrilled to have access to OpenEye’s industry-leading software in this effort. The OpenEye Toolkits have long been the backbone of our computer-aided drug discovery infrastructure, and access to the Orion NES Free Energy workflows allows us to run free energy calculations in mere hours.”

The ASAP Discovery Consortium is an Antiviral Drug Discovery (AViDD) U19 Center for Pathogens of Pandemic Concern funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), via a $68 million grant as part of the Antiviral Program for Pandemics (APP).

The NIH grant is for the initial three-year phase of the ASAP Discovery Consortium, which aims to deliver multiple drug candidates ready for evaluation in humans in the event of an ongoing or emerging pandemic threat. The project will maximize the use of an open science model that prioritizes global, equitable and affordable access to antiviral medicine, generating a wealth of antiviral data shared rapidly and openly.

ASAP builds on the successes of the COVID Moonshot, a global, open-science collaboration that began in March 2020 and rapidly identified potent antivirals targeting the main protease of the SARS-CoV-2 virus. In July 2021, Moonshot received $11M in funding from the Wellcome Trust to pursue an accelerated preclinical program via the World Health Organization Access to COVID Tools Accelerator (ACT-A) and is working with the Drugs for Neglected Diseases Initiative (DNDi) to pursue clinical trials with a straight-to-generics model.

The ASAP Discovery Consortium is led by PIs John Chodera (MSKCC), Alpha Lee (PostEra) and Peter Sjö (DNDi). ASAP partners include the Diamond Light Source (UK), the Weizmann Institute of Science (Israel), Medchemica (UK), Mount Sinai (USA), the Stanford University School of Medicine (USA) and the Fred Hutchinson Cancer Center (USA), as well as a vast global network of scientists and industry collaborators.

About ASAP

The AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium uses artificial intelligence and computational chemistry to accelerate structure-based open-science antiviral drug discovery and deliver oral antivirals for pandemics with the goal of global, equitable and affordable access. For more information about ASAP, including a complete list of diseases and drug targets and all open data that it has generated, visit https://asapdiscovery.org.

About Cadence

Cadence is a pivotal leader in electronic design, building upon more than 30 years of computational software expertise. The company applies its underlying Intelligent System Design^™ strategy to deliver software, hardware and IP that turn design concepts into reality. Cadence^® customers are the world’s most innovative companies, delivering extraordinary electronic products from chips to boards to systems for the most dynamic market applications, including consumer, hyperscale computing, 5G communications, automotive, mobile, aerospace, industrial and healthcare. For nine years in a row, Fortune magazine has named Cadence one of the 100 Best Companies to Work For. Learn more at www.cadence.com.

Category: Featured

View source version on businesswire.com: https://www.businesswire.com/news/home/20231207130587/en/

Cadence Newsroom

408-944-7039

newsroom@cadence.com

Source: Cadence Design Systems

FAQ

What is the company name and ticker symbol for the business unit providing molecular design software for the ASAP Discovery Consortium?

The company name is Cadence Molecular Sciences and the ticker symbol is CDNS.

What is the purpose of the $68 million NIH grant received by the ASAP Discovery Consortium?

The grant aims to support the development of antivirals to prevent future pandemics and deliver multiple drug candidates ready for evaluation in humans in the event of an ongoing or emerging pandemic threat.

Who is leading the ASAP Discovery Consortium?

The consortium is led by PIs John Chodera, Alpha Lee, and Peter Sjö.

What organizations and institutions are involved in the ASAP Discovery Consortium?

Partners include the Diamond Light Source (UK), the Weizmann Institute of Science (Israel), Medchemica (UK), Mount Sinai (USA), the Stanford University School of Medicine (USA), and the Fred Hutchinson Cancer Center (USA), as well as a vast global network of scientists and industry collaborators.

What is the goal of the ASAP Discovery Consortium?

The consortium aims to deliver multiple drug candidates ready for evaluation in humans in the event of an ongoing or emerging pandemic threat and to prioritize global, equitable, and affordable access to antiviral medicine.

What is the role of OpenEye's software in the ASAP Discovery Consortium?

OpenEye's software will aid in advancing therapeutics for under-researched diseases and to prepare for pandemics by enabling computational chemists to build a robust antiviral drug discovery pipeline using technology, structural biology, artificial intelligence (AI), machine learning, and computational chemistry.